The University of Nebraska Medical Center in Omaha has enrolled the first patient in a clinical trial in partnership with ANANDA Scientific for an investigational drug to treat post-traumatic stress disorder.
The phase 2 trial is led by principal investigator Matthew Rizzo, MD, according to a March 14 news release. Dr. Rizzo currently serves as the Reynolds Professor and Chair of the UNMC Department of Neurological Sciences.
The trial aims to enroll 180 participants to evaluate the effectiveness of Nantheia ATL5, a drug using cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology to treat PTSD.
Americans’ self-reported mental health has reached its lowest level in 24 years, with younger adults — especially women — experiencing…
Almost 500 mental health provider jobs have been eliminated in Colorado since the beginning of 2025, The Colorado Sun reported…
Penn Medicine’s Lancaster (Pa.) General Hospital opened a crisis walk-in center that provides immediate behavioral health assessments and treatments. The…
